CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Multimorbidity and neuroimaging biomarkers among cognitively normal persons
Authors
Jeremiah A. Aakre
Rabe E. Alhurani
+10 more
Yonas E. Geda
Clifford R. Jack
David S. Knopman
Walter K. Kremers
Val J. Lowe
Mary M. Machulda
Michelle M. Mielke
Ronald C. Petersen
Rosebud O. Roberts
Maria Vassilaki
Publication date
31 May 2016
Publisher
Barrow - St. Joseph\u27s Scholarly Commons
Doi
Cite
View
on
PubMed
Abstract
© 2016 American Academy of Neurology. Objective: To assess the cross-sectional association between multimorbidity and imaging biomarkers of brain pathology in the population-based Mayo Clinic Study of Aging (MCSA). Methods: The study consisted of 1,449 MCSA participants who were cognitively normal at the time of MRI. A subset of the participants also had 11C-Pittsburgh compound B (n 5 689) and 18fluorodeoxyglucose (n 5 688) PET scans available. Information on multimorbidity (defined as 2 chronic conditions) in the 5 years prior to the first imaging study was captured from the medical record using ICD-9 codes for chronic conditions and the Rochester Epidemiology Project medical records linkage system. The cross-sectional association of multimorbidity and imaging biomarkers was examined using logistic and linear regression models. Results: Among 1,449 cognitively normal participants (mean age 79 years; 50.9% men), 85.4% had multimorbidity (2 chronic conditions). Multimorbidity and severe multimorbidity (4 chronic conditions) were associated with abnormal Alzheimer disease (AD) signature meta-region of interest (meta-ROI) 18F-FDG hypometabolism (odds ratio [OR] 2.03; 95% confidence interval [CI] 1.10-3.77 and OR 2.22; 95% CI 1.18-4.16, respectively), and with abnormal AD signature MRI cortical thickness (OR 1.53; 95% CI 1.09-2.16 and OR 1.76; 95% CI 1.24-2.51, respectively), but was not associated with amyloid accumulation. Conclusions: Multimorbidity was associated with brain pathology through mechanisms independent of amyloid deposition and such neuronal injury and pathology was present before any symptomatic evidence of cognitive impairment. Longitudinal follow-up will provide insights into potential causal associations of multimorbidity with changes in brain pathology
Similar works
Full text
Available Versions
Barrow - St. Joseph's Scholarly Commons
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:scholar.barrowneuro.org:ne...
Last time updated on 27/02/2021